Trial Profile
An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2016
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Vandetanib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Sanofi
- 05 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 05 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 05 Jul 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.